Stocks: Reata Pharmaceuticals Inc (RETA) Price Target Raised to $39.00

Stocks: Reata Pharmaceuticals Inc (RETA) Price Target Raised to $39.00

Reata Pharmaceuticals Inc (NASDAQ:RETA) had its price target boosted by Citigroup Inc from $32.00 to $39.00 in a research report report published on Tuesday morning. They currently have a buy rating on the stock.

Several other equities research analysts have also recently commented on RETA. Zacks Investment Research cut Reata Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, January 18th. Robert W. Baird initiated coverage on Reata Pharmaceuticals in a research note on Tuesday, January 24th. They set an outperform rating and a $43.00 target price for the company. Stifel Nicolaus initiated coverage on Reata Pharmaceuticals in a research note on Wednesday, February 22nd. They set a buy rating and a $38.00 target price for the company. Piper Jaffray Companies reaffirmed an overweight rating and set a $48.00 target price on shares of Reata Pharmaceuticals in a research note on Monday, March 6th. Finally, Ladenburg Thalmann Financial Services initiated coverage on Reata Pharmaceuticals in a research note on Thursday, April 13th. They set a buy rating and a $55.00 target price for the company. Seven analysts have rated the stock with a buy rating, Reata Pharmaceuticals has an average rating of Buy and an average target price of $39.29.

Reata Pharmaceuticals (NASDAQ:RETA) opened at 22.30 on Tuesday. Reata Pharmaceuticals has a 52-week low of $11.03 and a 52-week high of $41.60. The stock’s 50 day moving average price is $22.17 and its 200 day moving average price is $24.20. The firm’s market capitalization is $498.27 million.

In related news, major shareholder Abbvie Inc. sold 450,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 28th. The stock was sold at an average price of $22.50, for a total transaction of $10,125,000.00. Following the completion of the sale, the insider now owns 1,190,473 shares of the company’s stock, valued at $26,785,642.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 62.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $216,000. Teachers Advisors LLC boosted its stake in shares of Reata Pharmaceuticals by 12.8% in the fourth quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock worth $221,000 after buying an additional 1,148 shares during the period. Interwest Venture Management Co. purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $285,000. Atlantic Trust Group LLC purchased a new stake in shares of Reata Pharmaceuticals during the first quarter worth approximately $285,000. Finally, Bessemer Group Inc. purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $380,000. 64.18% of the stock is owned by hedge funds and other institutional investors.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Related posts

Leave a Comment